Clinical Trial Update: Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating risk-adapted, proteomic-guided systemic therapy for previously untreated, advanced non-small cell lung cancer (Stage IIIC or S…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: University of California, Davis | Conditions: Non-small Cell Lung Cancer Stage IIIC, Non-small Cell Lung Cancer Stage IV | Phase 2 | Status: RECRUITING